Literature DB >> 18587567

No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam.

D Tomalik-Scharte, O Doroshyenko, J Kirchheiner, A Jetter, A Lazar, T Klaassen, D Frank, C Wyen, G Fätkenheuer, U Fuhr.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18587567     DOI： 10.1007/s00228-008-0503-9

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  2 in total

1.  Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers.

Authors:  D Tomalik-Scharte; A Jetter; M Kinzig-Schippers; A Skott; F Sörgel; T Klaassen; D Kasel; S Harlfinger; O Doroshyenko; D Frank; J Kirchheiner; M Bräter; K Richter; T Gramatté; U Fuhr
Journal:  Drug Metab Dispos       Date:  2005-09-23       Impact factor: 3.922

2.  Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam.

Authors:  E D Kharasch; A Walker; N Isoherranen; C Hoffer; P Sheffels; K Thummel; D Whittington; D Ensign
Journal:  Clin Pharmacol Ther       Date:  2007-06-06       Impact factor: 6.875
  2 in total
  1 in total

1.  Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency.

Authors:  Dorota Tomalik-Scharte; Dominique Maiter; Julia Kirchheiner; Hannah E Ivison; Uwe Fuhr; Wiebke Arlt
Journal:  Eur J Endocrinol       Date:  2010-09-15       Impact factor: 6.664
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.